Preferential killing of breast tumor initiating cells by N, N- Diethyl-2- [4-(phenylmethyl)phenoxy]ethanamine/tesmilifene

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 119-130

  Deng, Tao ^a   Liu, Jeff C ^a   Pritchard, Kathleen I ^b   Eisen, Andrea ^b,d   Zacksenhaus, Eldad ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; TESMILIFENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CARCINOGENIC ACTIVITY; CELL FUNCTION; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; EXPERIMENTAL MOUSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOGRAFT; MAMMARY GLAND; MOUSE; NONHUMAN; ONCOGENE NEU; PLEURA EFFUSION; PRIORITY JOURNAL; TUMOR CELL; TUMOR INITIATING CELL;

ANIMALS; ANTIGENS, CD24; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL ADHESION; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; PHENYL ETHERS; PLEURAL EFFUSION, MALIGNANT;

EID: 58849097669     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1708     Document Type: Article

References (52)

1. Pritchard Kl. The best use of adjuvant endocrine treatments. Breast 2003;12:497-508.
2. Hery C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008;19:1187-94.
3. Levine M, Eisen A. Anthracycline adjuvant chemotherapy, how much is enough? J Clin Oncol 2001;19: 599-601.
4. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92.
5. Dick JE. Breast cancer stem cells revealed Proc Natl Acad Sci U S A 2003;100:3547-9.
6. Al-Hajj M, Becker MW,Wicha M,Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004;14:43-7.
7. Pardal R, Clarke MF, Morrison SJ, et al. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902.
8. Dontu G, Al-Hajj M, Abdallah WM, et al. Stem cells in normal breast development and breast cancer. Cell Prolif 2003:36 Suppl 1:59-72.
9. Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003;3:832-44.
10. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7.
11. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8.
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
13. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells Nature 2004; 432:396-401.
14. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
15. + cancer stem cells in human liver cancer. Cancer Cell 2008;13:153-66.
16. Wu C, Wei Q, Utomo V, et al. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 2007;67:8216-22.
17. Hansford LM, McKee AE, Zhang L, et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007;67:11234-43.
18. SchattonT, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008; 451:345-9.
19. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
20. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 2006;103:11154-9.
21. + prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708.
22. Shackleton M.Vaillant F, Simpson KJ. et al. Generation of a functional mammary gland from a single stem cell. Nature 2006:439:84-8.
23. Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. Cancer Res 2007:67:8671 -81.
24. Cho RW, Wang X, Diehn M, et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008;26:364-71.
25. + cells with cancer stem cell characteristics. Breast Cancer Res 2008;10:R10.
26. ReyaT, Morrison SJ, Clarke MF. Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001:414:105-11.
27. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60.
28. + breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-85.
29. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008;7:309-13.
30. Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23.
31. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672 - 9.
32. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000;12:450-8.
33. Vincent M Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump. Med Hypotheses 2006;66: 715-31.
34. Brandes LJ, Queen GM, LaBella FS N.N-Diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs. Cancer Chemother Pharmacol 2000;45: 298-304.
35. Szincsak N, Hegyesi H, Hunyadi J, Falus A. Juhasz I. Different h2 receptor antihistamines dissimilarly retard the growth of xenografted human melanoma cells in immunodeficient mice. Cell Biol Int 2002;26: 833-6.
36. Brandes LJ, Bracken SP. The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)-phenoxy]ethamine.HCL. may potentiate doxorubicin in the treatment of metastatic breast cancer: results of a pilot study. Breast Cancer Res Treat 1998;49: 61 - 8.
37. Shank-Retzlaff ML, Raner GM, Coon MJ, Sligar SG. Membrane topology of cytochrome P450 2B4 in Langmuir-Blodgett monolayers. Arch Biochem Biophys 1998;359:82-8
38. Reyno L, Seymour L. Tu D, et al. Phase III study of N,N-diethyl-2- [4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol 2004;22:269-76
39. Raghavan D, Brandes LJ, Klapp K, et al Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol 2005;174:1808-13:discussion 1813.
40. Li Y, Hively WP, Varmus HE. Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 2000;19:1002 - 9
41. Guy CT, Webster MA, Schaller M, ParsonsTJ, Cardiff RD, Muller WJ. Expression of neu proto-oncogene in the mammary epithelium of transgenic mouse induces metastatic disease. Proc Natl Acad Sci U S A 1992:89: 10578 - 82.
42. Brandes LJ, Simons KJ, Bracken SP. Warrington RC. Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2- [4-(phenylmethyl)phenoxy]ethanamine-HCI, in combination with various single antineoplastic agents. J Clin Oncol 1994;12:1281 -90
43. YM Biosciences data in house.
44. Dontu G, Abdallah WM, Foley JM, et al In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-70.
45. Ponti D, Costa A, Zaffaroni N, et al Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-11.
46. Mani SA, Guo W, Liao MJ, et al The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15
47. Brandes LJ, La Bella FS, Warrington RC. Increased therapeutic index of antineoplastic drugs in combination with intracellular histamine antagonists. J Natl Cancer Inst 1991;83:1329-36
48. Kudoh K, Kikuchi Y, Hiramatsu H, et al Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin. Eur J Cancer 1997;33:122-8
49. Ramu A, Ramu N. Reversal of multidrug resistance by phenothiazines and structurally related compounds. Cancer Chemother Pharmacol 1992;30: 165-73
50. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 2007;6:2332-8.
51. Perou CM, SorlieT, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
52. Korkaya H, Paulson A, lovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion Oncogene 2008;27:6120-30